概览
Click Here to View the Preriminaly Program ( Japanese, English )
Click Here to View the JAM2022 site
In 2022, DIA events are returning to a face-to-face format. DIA is committed to delivering a safe and secure conference to all participants. This means, for this event all in-person participants must comply with our Event Safety Code of Conduct, which requires either vaccination, certificate of recovery, or proof of inability to be vaccinated alongside a valid PCR test. Please click here for more information regarding our Event Safety Code of conduct.
The theme of the 19th DIA Japan Annual Meeting is “New "Quest for the future"- Moving Creativity and Innovation Forward in "New Normal" - ”. This means that we who have experienced COVID 19 will explore the future in a new normal environment. COVID19 has brought us lives and environments that we have never experienced before. While face-to-face work declined dramatically, digital transformation accelerated at once. They also promoted extremely rapid development of vaccines and therapeutic agents, as well as new clinical trial models including telemedicine. In addition, the importance of self-care associated with refraining from visiting medical institutions and the importance of addressing the issue of infodemics were reaffirmed.
In the new normal environment that has brought about by COVID19, we are seeking to implement new clinical trials, implement safety measures, disseminate information, develop new modalities, and respond to self-care. There is a need for new Creativity and Innovation on pharmaceuticals, medical devices, regenerative medicine, and other products for the future. We wish to share and discuss how to proceed with this in advance, as well as the efforts, experiences and ideas of you, and to make it a conference to proceed further in advance. It is hoped that discussions will take place from a variety of positions and perspectives.
This year, we will hold the meeting in a hybrid format (In-person and Live Virtual) considering the status of expansion of new coronavirus infectious diseases. The following two types of lecture are planned.
- Live lectures: Live (partially recorded) speaks (and live panel discussions) on the day and date of each session. In principle, a live video of the day is recorded and can be viewed until the end of November.
- On-demand lectures: Prerecorded lectures (and panel discussions) are distributed. Recordings can be viewed from the first day of the annual meeting until the end of November.
We sincerely look forward to your participation.
项目委员会
-
Koji Iwasaki, PhD Professor, Academic Clinical Research Center,
Osaka University Hospital, Japan -
Tomiko Tawaragi Chief Director
RAD-AR, Japan -
Kazuhiko Ishida, MSc, RPh Director, Pharmacovigilance
Astellas Pharma Inc., Japan -
Naoki Isogawa, PhD Deputy head of SSI East Asia
UCB Japan, Japan -
Keiko Katsui, PhD Division of Research Integrity and Social Co-Creation
Japan Agency for Medical Research and Development (AMED), Japan -
Kana Maruyama Manager, Regulatory Labeling, Regulatory Affairs
Viatris Pharmaceuticals Japan Inc., Japan -
Sho Mizokawa, MBA, MSc, RPh Senior Manager, Development Project Management
Astellas Pharma Inc., Japan -
Takashi Moriya, PhD, MBA CEO Office, Executive Director
CMIC Holdings, Inc., Japan -
Hiroyuki Murakami Duputy Review Director, Office of New Drug I
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Noriaki Nagao, MPharm, PMP Director, Clinical Development Dept. , Pharmaceutical Division
JAPAN TOBACCO INC., Japan -
Atsuo Nakagawa, MD, PhD Assistant Professor, The Center for Clinical Research
Keio University School of Medicine, Japan -
Yukiko Nishimura, PhD, MSc President
NPO ASrid, Japan -
Katsuhiko Sawada, MPharm Director, Research and Development Dept.
Otsuka Medical Devices Co.Ltd., Japan -
Yasuharu Shibata, MSc Head of Clinical Data Management, Cliinical Data Management
MSD K.K., Japan -
Kazumi Sunamura Director, Regulatory Strategy & Policy 2
Pfizer R&D Japan, Japan -
Kazuyuki Suzuki, MSc Senior Lead strategy & Execution Patient Engagement group Cuntry Comms & Patient
Novartis Pharma K.K., Japan -
Keiko Tsumori, MSc Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Tetsuya Watanabe, RPh Senior Medical Director, Medical Affairs
Astellas Pharma Inc., Japan -
Miyoko Yamauchi Clinical Leader, Specialty Clinical Development Dept.
CHUGAI PHARMACEUTICAL CO., LTD., Japan -
Haruko Yamamoto, MD, PhD Director, Department of Data Science
National Cerebral and Cardiovascular Center, Japan -
Junichi Nishino, MSc, RPh Head, Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Goshi Ozawa, MS Representative Director & President, Japan / R&D Head
Juniper Therapeutix K.K., Japan -
Rie Matsui, RPh Senior Director, Regional Labeling Head for APAC, International Labeling
Pfizer R&D Japan G.K., Japan -
Junko Sato, PhD Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Shinichi Nishiuma, MD Executive officer, Chief Medical Officer
Aculys Pharma Inc,, Japan -
Sonoko Misawa, MD, PhD Associate Professor, Department of Neurology
Chiba University Graduate of Medicine, Japan -
Mika Ogasawara Data Quality Lead, Biometrics and Data Management
Pfizer R&D Japan G.K., Japan -
Taro Amagasaki, PhD Head, Analytics Japan
Novartis Pharma K.K., Japan -
Yukihiro Matsuda, MSc Director, Clinical Delivery
ICON Clinical Research GK, Japan -
Mitsuo Ishikawa, MPharm
Medii, Japan -
Mengyan Deng, PhD Senior Associate, Japan Regulatory Affairs
Eisai Co., Ltd., Japan -
Koichi GOTO Deputy Manager
CM Plus Corporation, Japan -
Nanako Hamazaki Tsukuba Clinical Research & Development Organization
University of Tsukuba, Japan -
Yuta Kasai Japan-Asia Clinical Development 2
Astellas Pharma Inc., Japan -
Tomoki Kato, MS Associate Manager, Clinical Quality Management Group, R&D Division
Daiichi Sankyo Company, Limited, Japan -
Fumitaka Kawasaki R&D Division, R&D Planning & Project Management Department
KAKEN PHARMACEUTICAL CO., LTD., Japan -
Tomoko Kondo, PhD, RPh Associare Professor
Joint Research Center for Human Retrovirus Infection, Japan -
Akiko Nishioka Clinical Research Associate, Clinical Operation
Novartis Pharma K.K., Japan -
Tetsuya Sasaki, PhD Department of International Clinical Development
National Cancer Center Hospital, Japan -
Chiaki Takeuchi Clinical Operation Lead
Abbvie GK, Japan -
Yuji Utsuno Reviewer, Advanced Review with Electronic Data Promotion Group
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Yusaku Yoshioka Office of Review Manegement Division of Innovation Support and Pharmaceutical Af
Pharmaceuticals and Medical Devices Agency (PMDA), Japan